• Log In or Create Account
  • CROI
  • Conference on Bacteriophages
  • RWHAP CLINICAL CONFERENCE
  • Podcasts
  • Slides
  • Question of the Week
  • Guidelines
  • Contact
Advanced Search
HIV Vaccines in 2026 and Beyond: Promise and Persistence - IAS-USA
  • CME Courses
    • HIV In-Person and Virtual Courses
    • Current On-Demand Courses
    • About Courses
  • CME Webinars
    • Upcoming Webinars
    • Current On-Demand Webinars
    • MATE Act CME
    • About Webinars
  • Dialogues
    • Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
    • On-Demand Dialogues
    • About Dialogues
  • Topics In Antiviral Medicine
    • Current Issues for CME
    • Previous Issues
    • TAM Policies and Practices
    • Permission Request Form
  • HIV Drug Resistance
    • HIV Drug Resistance Resources
    • HIV Drug Resistance Mutations Chart
    • Recent Webinars
    • Journal Articles
  • Fellow Resources
    • Resources for Fellows and Others New to the HIV Field
    • On-Demand Webinars for Fellows
    • IAS-USA Guidelines and Recommendations
    • On-Demand Webcasts
    • Research Collaborations
    • Additional Resources
  • About
    • Scientific Leadership Board
    • IAS-USA Leadership Award Recipients
    • Core Faculty
    • Mission
    • Staff
    • CME
    • Funding Information
    • Careers
    • Website Policies
    • Discrimination and Harassment Policy
    • Governance
    • Suggestions and Recommendations from San Francisco Locals
    • Donate
    • FAQs

HIV Vaccines in 2026 and Beyond: Promise and Persistence

HIV Vaccines in 2026 and Beyond: Promise and Persistence

HIV Vaccines in 2026 and Beyond: Promise and Persistence
Presenter: Katharine J. Bar, MD

Slides

On-Demand Webcast

Podcast

iasusa · HIV Vaccines in 2026 and Beyond: Promise and Persistence

HIV Vaccines in 2026 and Beyond: Promise and Persistence - IAS-USA

131 Steuart St, Suite 500, San Francisco, CA 94105

Phone: (415) 544-9400 | info@iasusa.org

  • Home
  • Activities
  • Resources
  • About
  • Contact
  • Login
  • Careers
  • Donate
  • Website Policies
© 2026 International Antiviral Society–USA. All Rights Reserved.
  • CROI
  • Conference on Bacteriophages
  • RWHAP CLINICAL CONFERENCE
  • Podcasts
  • Slides
  • Question of the Week
  • Guidelines
  • Contact
  • CME Courses
    • HIV In-Person and Virtual Courses
    • Current On-Demand Courses
    • About Courses
  • CME Webinars
    • Upcoming Webinars
    • Current On-Demand Webinars
    • MATE Act CME
    • About Webinars
  • Dialogues
    • Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
    • On-Demand Dialogues
    • About Dialogues
  • Topics In Antiviral Medicine
    • Current Issues for CME
    • Previous Issues
    • TAM Policies and Practices
    • Permission Request Form
  • HIV Drug Resistance
    • HIV Drug Resistance Resources
    • HIV Drug Resistance Mutations Chart
    • Recent Webinars
    • Journal Articles
  • Fellow Resources
    • Resources for Fellows and Others New to the HIV Field
    • On-Demand Webinars for Fellows
    • IAS-USA Guidelines and Recommendations
    • On-Demand Webcasts
    • Research Collaborations
    • Additional Resources
  • About
    • Scientific Leadership Board
    • IAS-USA Leadership Award Recipients
    • Core Faculty
    • Mission
    • Staff
    • CME
    • Funding Information
    • Careers
    • Website Policies
    • Discrimination and Harassment Policy
    • Governance
    • Suggestions and Recommendations from San Francisco Locals
    • Donate
    • FAQs
Practice Question of the Week

October 6, 2026: Drug-Drug Interactions With Antiretroviral Regimens

A 75-year-old person with HIV was no longer able to tolerate oral antiretroviral therapy and switched to lenacapavir (LEN) + cabotegravir (CAB) (intramuscular rilpivirine was not recommended due to the presence of nonnucleoside reverse transcriptase resistance mutations). Four weeks after the most recent injection, he had a cerebrovascular event. Clopidogrel was initiated by the neurologist. Which of the following best describes the risk of drug-drug interactions in this setting?
Register for the Chicago Course
View Archived Questions
Leave Feedback
Subscribe